Bullish View on Spruce Biosciences; Kroger Posts Mixed Results
- September 08th, 2023
- 415 views
Spruce Biosciences, Inc. (Nasdaq: SPRB), a pharmaceutical company, was upgraded from Market Perform to Outperform by SVB Leerink, accompanied by a revised price target increase from $3 to $9.
Given that $SPRB closed at $2.23 on Thursday, this adjusted price target suggests a potential upside of $6.77 per share or approximately 303.13%, based on the assessment by the investment firm.
In other news, The Kroger Co. (NYSE: KR), a major retail corporation, reported second-quarter 2023 earnings of $0.96 per share, surpassing the consensus EPS estimate of $0.91. The company's quarterly sales amounted to $33.85 billion, slightly below analysts' projected revenue of $34.13 billion for the period.
$KR was trading at $44.54 in pre-market, down $0.99 (-2.17%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login